6.63亿“抄底”，石药集团拿下知名药企控股权|重生局_老虎社区_美港股上老虎

6.63亿“抄底”，石药集团拿下知名药企控股权|重生局

北京药研汇02-13

近日，此前一度面临退市风险的湖南景峰医药正式官宣破产重整，其重整计划取得重要突破。根据当日公布的重整计划草案，石药控股集团有限公司作为牵头投资人，联合其余18家重整参与方，将共同受让景峰医药转增的879,774,351股股份，总投资额约20.61亿元。这不仅仅是简单的资本运作，更是医药行业在集采寒冬下的一次“大鱼吃小鱼”。石药集团一出手就是6.63亿，直接拿下控股权。昔日医药“新星”ST景峰陨落，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2611169820?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-13 18:13","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2611169820","market":"hk","top_or_hot":-1,"title":"6.63亿“抄底”，石药集团拿下知名药企控股权|重生局","media":"北京药研汇","content":"<div>\n<p>近日，此前一度面临退市风险的湖南景峰医药正式官宣破产重整，其重整计划取得重要突破。根据当日公布的重整计划草案，石药控股集团有限公司作为牵头投资人，联合其余18家重整参与方，将共同受让景峰医药转增的879,774,351股股份，总投资额约20.61亿元。这不仅仅是简单的资本运作，更是医药行业在集采寒冬下的一次“大鱼吃小鱼”。石药集团一出手就是6.63亿，直接拿下控股权。昔日医药“新星”ST景峰陨落，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021319574595410d29&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>6.63亿“抄底”，石药集团拿下知名药企控股权|重生局</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n6.63亿“抄底”，石药集团拿下知名药企控股权|重生局\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-13 18:13 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021319574595410d29&s=b><strong>北京药研汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近日，此前一度面临退市风险的湖南景峰医药正式官宣破产重整，其重整计划取得重要突破。根据当日公布的重整计划草案，石药控股集团有限公司作为牵头投资人，联合其余18家重整参与方，将共同受让景峰医药转增的879,774,351股股份，总投资额约20.61亿元。这不仅仅是简单的资本运作，更是医药行业在集采寒冬下的一次“大鱼吃小鱼”。石药集团一出手就是6.63亿，直接拿下控股权。昔日医药“新星”ST景峰陨落，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021319574595410d29&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1226288253.USD","symbol_name":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021319574595410d29&s=b","article_id":"2611169820","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021319574595410d29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2611169820","pubTimestamp":1770977633,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近日，此前一度面临退市风险的湖南景峰医药正式官宣破产重整，其重整计划取得重要突破。根据当日公布的重整计划草案，石药控股集团有限公司作为牵头投资人，联合其余18家重整参与方，将共同受让景峰医药转增的879,774,351股股份，总投资额约20.61亿元。石药集团一出手就是6.63亿，直接拿下控股权。根据重整计划草案，仅石药集团受让股份的对价就达6.63亿元，后续可能还需持续投入资源，帮助该公司恢复经营活力。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","BK1521":"挪威政府全球养老基金持仓","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","BK1191":"制药","01093":"石药集团","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","IE0008368742.USD":"首域中国增长基金I Acc","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","BK1515":"抗疫概念","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC"},"translate_title":"663 million \"bargain hunting\", CSPC won a controlling stake in a well-known pharmaceutical company | Rebirth Bureau","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1.5},"content_text":"近日，此前一度面临退市风险的湖南景峰医药正式官宣破产重整，其重整计划取得重要突破。根据当日公布的重整计划草案，石药控股集团有限公司作为牵头投资人，联合其余18家重整参与方，将共同受让景峰医药转增的879,774,351股股份，总投资额约20.61亿元。这不仅仅是简单的资本运作，更是医药行业在集采寒冬下的一次“大鱼吃小鱼”。石药集团一出手就是6.63亿，直接拿下控股权。昔日医药“新星”ST景峰陨落，破产重整能否迎来新生？从2024年7月进入预重整阶段，到2025年10月法院正式受理重整申请，景峰医药的“自救之路”已走过一年多。值得关注的是，这场重整并非无序的债务清算，而是早已引入产业资本的“精准施救”—2024年8月，行业龙头石药集团便确定为战略投资人并缴纳保证金，其派出的刘树林等高管已接任景峰医药总裁及法定代表人等核心岗位，实现了管理层面的“换血”。景峰医药（ST景峰）走到今天这一步，可以说是“集采政策下的典型牺牲品”*。核心产品崩塌：景峰医药曾经的王牌产品是参芎葡萄糖注射液（中药注射剂），一度年销超10亿。但随着医保目录调整和集采落地，这款产品直接被踢出医保，瞬间失去了市场根基。巅峰时期的景峰医药，有50个药物品种入选医保目录，更凭借在心脑血管、肿瘤、骨科等核心领域的布局，连续多年跻身行业百强，2020年更是同时入选“中国中药企业TOP100”和“中国药品研发综合实力TOP100”。好景不长，随着医药行业政策环境变化，特别是带量采购、医保控费等政策的深入推进，景峰医药的核心产品面临巨大价格压力。公司主力品种如玻璃酸钠注射液、瑞格列奈等产品的市场份额和利润率均受到显著影响。转型失败：面对危机，景峰试图转型，推出了玻璃酸钠注射液等新品，试图“以价换量”，但最终未能成功培育出新的收入支柱。景峰医药曾经引以为傲的产品线也陷入增长瓶颈，虽然参芎葡萄糖注射液、心脑宁胶囊等核心产品仍在医保目录内，但市场份额被原研药和同类仿制药不断挤压。2024年，公司甚至因2023 年度经审计净资产为负被实施退市风险警示，股票简称首次变更为“*ST景峰”，虽在2025年6月因净资产转正短暂“摘星”，但经营基本面并未得到根本改善。石药的入局并非偶然。这次重整的总盘子高达20.61亿元，但石药集团作为牵头产业投资人，只花了6.63亿元就拿下了约4.57亿股（占总受让股数的51.9%），认购价仅为每股1.45元，成功实现了控股，捡了个大“便宜”？从产业协同看，景峰医药在心脑血管、骨科领域的核心产品与石药的抗肿瘤管线形成互补，而景峰的药品批文与生产基地，恰好填补了石药在中药与注射剂平台的布局空白。景峰医药主要聚焦于心血管疾病、骨科疼痛疾病及肿瘤疾病等热门治疗领域，旗下拥有心脑宁胶囊、镇痛活络酊、玻璃酸钠注射液、榄香烯系列等重点产品。此外，公司所在的常德市具备显著的产业资源优势，拥有亚洲最大的甾体原料药和中间体生产出口基地、全国最大的酶制剂生产出口基地，这或将成为公司未来发展可依托的重要基础。根据重整计划草案，仅石药集团受让股份的对价就达6.63亿元，后续可能还需持续投入资源，帮助该公司恢复经营活力。对蔡磊（景峰医药实际控制人蔡东晨之子）来说，上任首席执行官后的重要工作之一或是推动景峰医药顺利完成重整。成功重整景峰医药不仅是其面临的首场关键考验，其最终成效或将深刻影响景峰医药在石药体系中的战略定位。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}